Background
Stratified medicine seeks to identify gene signatures predicting whether a patient will benefit from a treatment. We evaluated several approaches to identify such signatures using high-dimensional Cox models in randomized clinical trials (RCT).
Methods
We investigated four approaches: penalize biomarker main effects and biomarker-by-treatment interactions using a lasso penalty (full-lasso); control of main effects by principal components or ridge penalty, and lasso on interactions (sPCA+lasso or ridge+lasso); and 'modified covariates' in a penalized regression model (Tian et al. 2014) . We performed simulations under null and alternative scenarios by varying the sample size n, number of biomarkers H, number of true main effects or treatment-modifiers, effect sizes and correlations. We proposed two novel measures of treatment effect prediction for gene signatures: a difference in C-indices and a Wald-based interaction statistic. We used gene expression data from a RCT of adjuvant chemotherapy in non-small cell lung cancer (n=133) for illustration.
Results
When n=500 and H=20 or 100, methods performed similarly in null scenarios apart from the full-lasso that gives poor results in presence of main effects only. In alternative scenarios: the ridge+lasso and the full-lasso predicted well the treatment benefit for future patients; the modified covariates approach performed poorly when also main effects were present. More extensive simulation results will be presented. In the lung cancer trial, the full-lasso and the ridge+lasso selected a gene signature with four and seven treatment-modifiers.
Conclusion
Preliminary results suggest that ridge+lasso and full-lasso are promising approaches in high-dimensional Cox models to predict the treatment benefit. 
